Mablink is incubated within Pulsalys (French TTO of Lyon-St Etienne), which endowed it with €380,000 to carry out the preclinical proof of concept of its ADC drug candidate MBK-102 in Non-Hodgkin’s Lymphoma.
PULSALYS, the DeepTech innovation incubator and accelerator of Lyon & St Etienne, builds the innovative products and services of tomorrow, by transforming the scientific discoveries made in the University of Lyon laboratories into economic opportunities. PULSALYS builds and develops innovative projects with high technological potential that form the basis for the creation of DeepTech startups or competitive advantages for existing companies. PULSALYS is a key player for the attractiveness and the economic development of the territory.